- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Recent successes don't change Lilly's outlook
February 9, 2011
J.K. WallEli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past
18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have
paltry sales prospects.
MoreLilly collaboration with outside researchers yields first deal
February 8, 2011
Chris O'MalleyEli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz
said it's just the first of many such collaborations.
MoreTechnicality delays council's North of South vote
February 8, 2011
Tom HartonA technicality caused the City-County Council on Monday night to put off a final vote on the massive North of South mixed-use
project slated to be built on 14 acres north of the Eli Lilly and Co. corporate campus.
MoreStruggling Lilly turns to antidepressant Cymbalta for lift
February 5, 2011
Greg AndrewsCymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition
arrives in 2013.
More2010 compensation fell about 20 percent for top Lilly execs
February 4, 2011
J.K. WallCompensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as
the company struggled to bring new medicines to market.
MoreLilly, Bristol-Myers halt enrollment in lung-cancer trial
February 2, 2011
J.K. WallEli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung
cancer drug over concerns about patients developing blood clots.
MorePotential competitor to Lilly drug shows promise in study
February 2, 2011
IBJ Staff and Bloomberg NewsSanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective
as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
MoreLilly's fourth-quarter profit surges, topping analysts' predictions
January 27, 2011
J.K. WallThe Indianapolis-based drugmaker earned $1.2 billion in the quarter, compared with $915 million in the same period a year
ago. Profit per share beat Wall Street forecasts by a penny.
MoreLilly product gets boost; Wall Street yawns
January 26, 2011
J.K. WallEli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease,
but so far analysts are unimpressed.
MoreHead of Lilly's oncology unit resigning
January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
MoreVanderbilt rejected by high court on Cialis patents
January 24, 2011
Bloomberg NewsSupreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against
Eli Lilly's Icos subsidiary.
MoreIndiana companies prepping for burst of acquisitions
January 22, 2011
Francesca JaroszConditions are ripe for a barrage of mergers and acquisitions to take place this year.
MoreLilly imaging drug fails to win FDA panel's backing
January 21, 2011
Bloomberg NewsEli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA
advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results
of brain scans are read consistently, they said.
MoreDeCoudreaux leaving Lilly for top job at Mills College
January 20, 2011
J.K. WallAlecia DeCoudreaux, the top attorney for Eli Lilly and Co.’s U.S. unit and an active community volunteer, will leave
to become president of Mills College in California on July 1.
MoreDown on luck, Lilly finds comfort in pets
January 19, 2011
J.K. WallEli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
MoreCarmel firm gets FDA approval for lice treatment
January 18, 2011
IBJ StaffParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MorePanel says Lilly’s Solpura isn’t ready for approval
January 12, 2011
Bloomberg NewsEli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that
isn’t derived from pig parts.
MoreDeal could give Lilly full diabetes deck
January 12, 2011
J.K. WallEli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy
that some consultants think is key to pharma companies’ futures.
MoreUPDATE: Analysts praise Lilly diabetes deal with Boehringer
January 11, 2011
J.K. WallThe deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with
five drugs and payments to be named later—but analysts and investors generally liked what they heard.
MoreLilly agrees to pay up to $1.2B for diabetes drugs
January 11, 2011
J.K. WallA complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreLilly bumped up federal lobbying in third quarter
January 4, 2011
Associated PressThe Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the
same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
MoreRoche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.
For those who let this information strike a nerve, remember that this is still the America that allows the freedom to achieve dreams and goals. Should you really chastise those who are given a perk on a deal that is supported by the consumer (that is until they don't like the deal anymore due to envy) or should the dream of rewards for working be looked at a little closer? I say lets stick to the deal, go to work,earn our keep, shoot for dreams, change our jobs to have that dream or shut up about others achievements ..............while we are still afforded this liberty of America !
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.